US2003186375A1PendingUtilityA1
Nuclear myosin I beta with a 16 amino acid N-terminal extension
Est. expiryJun 29, 2020(expired)· nominal 20-yr term from priority
C07K 14/4716A61K 2039/505C07K 16/18G01N 33/6887G01N 2500/00
37
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to a molecular motor actin binding protein, in particular, to Nuclear Myosin I β (NMI β) containing a 16 amino acid N-terminal extension involved in transcription. More particularly, this invention is directed to a molecule with oligonucleotide sequence coding for a protein nuclear Myosin I β (NMI β) containing a 16 amino acid N-terminal extension that co-localizes with, and forms functional complexes with, RNA polymerase II. This invention is also directed to polyclonal and monoclonal antibodies to the 16 amino acid N-terminal extension that block in vitro RNA synthesis. This invention is also directed to administration to a cell of polyclonal or monoclonal antibodies to the NMI β 16 amino acid N-terminal extension sequence or to an epitope within that sequence to inhibit transcription. Other inhibitors are also suitable. This invention may be used to treat illness through targeted inhibition of cell proliferation.
Claims
exact text as granted — not AI-modified1 . A Nuclear Myosin I β protein comprising a 16 amino acid N-terminal extension added to a cytoplasmic Myosin I β protein amino acid sequence.
2 . The Nuclear Myosin I β protein of claim 1 wherein the amino acid sequence comprises:
mryrasalgs
dgvrvtmesa
ltardrvgvq
dfvllenfts
eaafienlrr
rfrenliyty
igpvlvsvnp
yrdlqiysrq
hmeryrgvsf
yevpphlfav
adtvyralrt
errdqavmis
gesgagktea
tkrllqfyae
tcpapergga
vrdrllqsnp
vleafgnakt
lmdnssrfg
kymdvqfdfk
gapvgghils
ylleksrvvh
qnhgernfhv
fyqlleggee
etlrrlgler
npqsylylvk
gqcakvssin
dksdwkvmrk
alsvidfted
evedlisiva
svlhlgnihf
aadedsnaqv
ttenqlkylt
rllgvegttl
realthrkii
akgeellspl
nleqaayard
alakavysrt
ftwlvrkinr
slaskdaesp
swrsttvlgl
ldiygfevfq
hnsfeqfcin
ycneklqqlf
ieltlkseqe
eyeaegiawe
pvqyfimnkii
cdlveekfkg
iisildeecl
rpgeatdltf
lekledtvkp
hphflthkla
dqktrksldr
geftllhyag
evtysvtgfl
dknndllfrn
lketmcssmn
pimaqcfdks
elsdkkrpet
vatqfkmsll
qlveilrske
payircikpn
dakqpgrfde
vlirhqvkyl
glmenlrvrr
agfayrrkye
aflqrykslc
petwpmwagr
pqdgvavlvr
hlgykpeeyk
mgrtkifirf
pktlfateds
levrrqslat
kiqaawrgfh
wrqkflrvkr
saieiqswwr
gtlgrrkaak
rkwaaqtirr
lirgfilrhs
prepenaffl
dhvrasflln
lrrqlprnvl
dtswptpppa
lreasellre
lcmknmvwky
crsispewkq
qlqqkavase
ifkgkkdnyp
qsvprlfist
rlgteeispr
vlqslgsepi
qyavpvvkyd
rkgykprprq
llltpsavvi
vedakvkqri
dyanltgisv
sslsdslfvl
hvqrednkqk
gdvvlqsdhv
ietltktals
adrvnninin
qgsitfaggp
grdgiidfts
gsellitkak
nghlavvapr
lnsr.
3 . An oligonucleotide sequence encoding the Nuclear Myosin I β of claim 1 .
A cDNA molecue with the following nucleotide sequence:
1
ggagcggggc gccgggtccg gcaggatgcg ctaccgggca tcggccctgg gcagtgacgg
61
ggttcgagtg accatggaga gcgccttgac tgcccgagac cgggtagggg tgcaggactt
121
tgtcctgctg gagaatttca ccagtgaggc tgccttcatt gagaacctcc ggcggcggtt
181
ccgggagaac ctcatttata cctacatcgg tcctgtccta gtctctgtca atccctaccg
241
agacctacag atctacagcc ggcagcatat ggaacgctac cgtggtgtca gtttctatga
301
agtaccacct catttgtttg cagtggctga cactgtatac cgggcacttc gtactgagcg
361
tcgggaccag gcagtgatga tttctggaga gagtggggca ggcaagacag aggccaccaa
421
gagactgctc cagttctatg cagagacctg cccagcccct gaacggggtg gcgcagtgcg
481
agaccgcctg ttgcagagca accccgtgtt agaggccttt gggaatgcca agactctccg
541
caacgataac tccagccggt ttggaaagta catggatgtg cagtttgact tcaagggtgc
601
ccccgtggga ggccacattc tcagttacct cctggaaaag tcccgggtgg tgcaccaaaa
661
tcacggagag cggaacttcc acgtctttta ccagctactg gaggggggcg aggaggagac
721
tctccgtcgg ctgggcttgg aacggaaccc ccagagctac ttgtacctgg tgaagggcca
781
gtgtgccaag gtctcctcca tcaacgacaa gagtgactgg aaggttatga ggaaggcgct
841
gtccgtcatt gacttcactg aggatgaagt ggaggacttg ctcagcatcg tggccagcgt
901
cctacatctg ggcaacatcc actttgctgc tgacgaggac agcaatgccc aggttactac
961
tgagaaccag ctcaaatatc tgaccaggct ccttggtgtg gaaggtacaa cacttaggga
1021
agccctgacc cacaggaaga tcatcgccaa gggggaagag ctcctgagcc cactgaacct
1081
tgaacaggcg gcatatgcaa gggatgcgct tgccaaggct gtgtacagcc ggacattcac
1141
ctggctggtc agaaagatca ataggtcact ggcctctaag gacgctgaga gccccagctg
1201
gcgaagcacc acggttcttg ggctcctgga catttacggc tttgaagtgt ttcagcataa
1261
cagcttcgag cagttctgca tcaactactg caatgagaag ctgcagcagc tcttcatcga
1321
gctgactctc aagtcggagc aggaggaata cgaggctgag ggcatcgcgt gggaacctgt
1381
ccagtacttc aacaacaaga tcatctgtga cctggtagag gagaagttca agggcatcat
1441
ctccatcttg gatgaagagt gcctgcgtcc tggggaggcc acggacctga cctttctgga
1501
gaagttggag gacactgtca agccccaccc tcacttcctg acgcacaagc tcgctgacca
1561
gaagaccagg aaatccctag accgagggga gttccgcctt ctgcattatg ctggagaggt
1621
gacctacagt gtgactgggt ttctggataa aaacaatgac ctcctcttcc ggaacctgaa
1681
ggagaccatg tgcagctcaa tgaaccccat catggcccag tgctttgaca agagtgagct
1741
cagtgacaag aagcggccag gacggtggcc acccagttca aagatgagcc tcctgcagct
1801
cgtggagatc ctgaggtcta aggagcctgc ctatatccgg tgcatcaagc caaacgacgc
1861
caagcagccg ggtcgctttg atgaggtgct catccgacat caggtgaagt acctgggact
1921
gatggagaat ctgcgcgtgc gcagagctgg ctttgcctat cgtcgcaaat atgaggcttt
1981
cctgcagagg tacaagtcac tgtgcccaga gacatggccc atgtgggcag gacggcccca
2041
ggatggtgtg gccgtgttgg tcagacacct cggctacaag ccagaagagt acaaaatggg
2101
caggactaag atcttcatcc gattccccaa gaccttattt gccacagagg actccctgga
2161
agtccggcgg cagagtctag ccaccaagat ccaggcggcc tggaggggct ttcattggcg
2221
acagaaattt ctccgggtga agcgatcagc catctgtatc cagtcatggt ggcgtggcac
2281
actgggccgg aggaaggcag ccaagaggaa gtgggcagcc cagaccatcc gtcgactcat
2341
ccgtggcttc attttgcgcc attcaccccg gtgccctgag aatgccttct tcttggacca
2401
cgtgcgcgcc tcatttttgc ttaacctgag gcggcaactg ccccggaatg ttctggacac
2461
ctcctggccc acacccccac ctgccctgag agaggcctca gaactgctac gggaactgtg
2521
catgaagaac atggtgtgga agtactgccg gagcatcagc cctgagtgga agcagcagct
2581
gcagcaaaag gcggtggcta gtgaaatttt caagggcaag aaggacaact acccccagag
2641
tgtccccaga ctcttcatta gcacacggct tggcacagag gagatcagcc ccagagtgct
2701
tcaatccttg ggctctgaac ccatccagta tgccgtgccc gtggtaaaat acgaccgtaa
2761
gggttacaag cctcgccccc ggcagctgct gctcacgccc agtgctgtgg tcattgtgga
2821
ggatgctaaa gtcaagcaga gaattgatta tgccaaccta accggaatct ctgtcagtag
2881
cctgagtgat agcctatttg tgcttcacgt gcagcgtgaa gacaacaagc agaagggaga
2941
tgtggtgctg cagagtgatc atgtgatcga gacactaacc aagacggccc tcagtgctga
3001
ccgcgtgaac aatatcaaca tcaaccaggg cagcataacg tttgcagggg gtccaggcag
3061
ggacggcatc attgacttca catcgggctc agagcttctc atcaccaagg ctaagaatgg
3121
ccacctggct gtggtggccc cacggctgaa ttctcggtga tgaaggctgc ggtggaccgc
3181
tcctgactcc tgatgcttcc cttagtcccc tcctcccctc cgacttacca aaaactcaag
3241
cttccaaaca gggatccatg gacaccctca aaacccacgc tgcaaactcc tgccttctgc
3301
tcgccccctc ttgaggtgat caggagccag ggagctaccc catgagtggg ccaggccggg
3361
ccacaccaat agaaaagcag aggcctgagc aggccaggcc agccctctgc tgatgccaaa
3421
tatctaagac aagggaattt taactgaggt tttctctgag attttttgat gctttatagg
3481
aaactatttt tttaagaaag ccattttcct accctaaaca cactggatgt gtttttccct
3541
gcctcgaaca gggcaaggaa tgtaactgaa agactgactg ggctgggctg gaaggtcctc
3601
ttcttggcca acccttcctt attcccttgt ctgcctgtcc atccacctgc accttttag
3661
cca.
5 . A peptide comprising-an amino acid sequence MRYRASALGSDGVRVT.
6 . A cDNA molecule encoding the peptide of claim 4 .
7 . The peptide of claim 5 comprising an epitope with the amino acid sequence FLAG.
8 . An antibody directed to the Nuclear Myosin I β protein of claim 2 .
9 . An antibody directed to the peptide of claim 4 .
10 . The antibody of claim 7 , wherein the antibody is a monoclonal antibody.
11 . An antibody directed to the peptide of claim 7 .
12 . A functional complex formed between one RNA polymerase II.
13 . A method for inhibiting cell proliferation, said method comprising:
(a) obtaining at least one antibody to the peptide of claim 5; and (b) administering the antibody to an organism so that the antibody contacts cells.
14 . The method of claim 13 wherein the antibody is a monoclonal antibody.
15 . The method of claim 13 wherein the antibody is a synthetic compound.
16 . A method for inhibiting cell proliferation, said method comprising
a) obtaining an antisense oligonucleotide to the cDNA of claim 3; (b) contacting the cDNA with the antisense oligonucleotide to prevent expression of the cDNA and reduce cell proliferation.
17 . A method for screening a candidate agent that inhibits transcription, said screening method comprising the antibodies in claim 9 .
(a) providing proliferating cells; (b) contacting the cells with the candidate agent; (c) determining whether nuclear myosin I β (MNI β) is translocated to the nucleus of the cells; and (d) inferring that the candidate agent is an inhibitor of cell proliferation if NMI β is not detected in the cells nucleus.Join the waitlist — get patent alerts
Track US2003186375A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.